__NUXT_JSONP__("/drugs/Ecromeximab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"292819-64-8",chebiId:b,chemicalFormula:b,definition:"A low-fucose, human-mouse chimeric IgG1 monoclonal antibody with potential antineoplastic activity targeting at the ganglioside GD3, a surface antigen expressed on many malignant melanoma cells. Monoclonal antibody KW-2871 binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells. This agent is prepared by fusing murine immunoglobulin (Ig) light and heavy variable regions derived from the murine IgG3 antibody KM-641 to a human constant (Fc) region. The low fucose content of the oligosaccharide side chains of this antibody may enhance binding of the antibody Fc region to lymphocyte Fc receptors.",fdaUniiCode:"M76FX2JZRM",identifier:"C61095",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C129822","C20401"],synonyms:["Chimeric Monoclonal Antibody KW-2871","ECROMEXIMAB",a,"Immunoglobulin G1, Anti-(Gd3 Ganglioside) (Human-Mouse Monoclonal Km871 Gamma-1-Chain), Disulfide with Human-Mouse Monoclonal KM871 Kappa-Chain, Dimer","KM871","KW-2871","Monoclonal Antibody KW-2871"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FEcromeximab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Ecromeximab","","2021-10-30T13:41:21.123Z")));